NEHTA

HealthITAnalytics | February 10, 2020

A team of scientists from Purdue University and other research institutions around the world leveraged data mining techniques to better understand trends in the gene therapy field in respect to nonviral vectors. With the global gene therapy market expected to reach $13 billion by 2024, researchers are seeking to understand as much as they can about how these treatment can target cancer and other diseases. Purdue scientists joined forced with researchers from around the globe to learn more about ...

HEALTHTECH SECURITY, DIGITAL HEALTHCARE

CereCore® | December 09, 2022

CereCore announced they are expanding their healthcare information technology (IT) services including electronic patient record (EPR), technical and IT staffing services into the United Kingdom in order to support the digital transformation that will help patients, clinicians and carers to manage and view healthcare records. "For close to 30 years, we have been serving communities in the US by supporting hospitals and clinics through the various stages of healthcare technology ...

HITInfrastructure | January 21, 2020

Masimo, a global leader in noninvasive monitoring technologies and connectivity tools for hospitals, recently announced a definitive agreement to acquire the connected care assets from California-based NantHealth for $47.25 million. NantHealth’s connected care assets, which include the DCX device connectivity, VCX patient vitals software, HBox connectivity hub, and Shuttle interface cable, provide medical device interoperability to hospitals and health system. Masimo will leverage NantHeal...

HEALTH TECHNOLOGY

Antengene Corporation Limited | September 19, 2022

Antengene Corporation Limited a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. This ODD will help Antenge...